Please login to the form below

Not currently logged in
Email:
Password:

Lonza to buy Arch Chemicals for $1.4bn

Life science industry suppliers, Lonza, are to acquire outstanding shares of biocides company Arch Chemicals for $47.20 per share – around $1.4bn in total

Life science industry suppliers, Lonza, are to acquire outstanding shares of biocides company Arch Chemicals for $47.20 per share – around $1.4bn in total.

A tender offer has been agreed between the two companies, subject to conditions including clearance from antitrust regulatory authorities.

Switzerland-based Lonza said it expects to commence the tender offer by July 15, 2011 and to complete the tender offer later in 2011.

According to the company, once the transaction is complete, Lonza will have the world's leading microbial control business, with related products being used in such areas as water treatment, hygiene and materials protection.

The micriobial market is estimated to have a global value of around $10bn, and a growth rate of four to six per cent every year.

Stefan Borgas, CEO of Lonza, said: "Lonza and Arch Chemicals offer highly complementary products and technologies and together will be the global leader in controlling unwanted microbes. The business will enjoy a strong platform for accelerated future growth for the benefit of all our stakeholders."

12th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics